Hims & Hers Scrutiny: Compounded GLP-1 Drug Risks

Hims & Hers investment narrative shifts amid legal scrutiny on compounded GLP-1 agonists. A January 2026 antitrust lawsuit accuses Eli Lilly and Novo Nordisk of blocking compounded Mounjaro and Wegovy. This raises uncertainties for telehealth providers reliant on these affordable weight management options.

New Antitrust Lawsuit Targets GLP-1 Giants
Regulatory Risks for Compounded GLP-1s
Analyst Perspectives on GLP-1 Dependencies
Implications for GLP-1 Access and Weight Management

The telehealth company Hims & Hers, known for its weight-loss offerings, now grapples with investor concerns centered on its dependence on compounded GLP-1 agonist drugs. Legal and regulatory uncertainties in this segment threaten long-term viability, especially as original manufacturers defend their market dominance.

New Antitrust Lawsuit Targets GLP-1 Giants

On January 14, 2026, Strive Specialties Inc. filed an antitrust lawsuit against Eli Lilly and Novo Nordisk. The complaint alleges anti-competitive practices aimed at preventing telehealth providers and pharmacies from offering compounded versions of blockbuster GLP-1 drugs like Mounjaro (tirzepatide) and Wegovy (semaglutide).

Although Hims & Hers is not named as a defendant, its growth heavily relies on this market. The case highlights intense competition in the GLP-1 weight loss space and signals aggressive patent protection efforts by pharmaceutical leaders.

Regulatory Risks for Compounded GLP-1s

If supply shortages of branded drugs like Wegovy and Ozempic resolve, FDA exemptions for pharmacy compounding may end.
Tighter regulations could limit access to lower-cost compounded alternatives.
This directly affects telehealth models dependent on compounded semaglutide and tirzepatide for weight management.

Analyst Perspectives on GLP-1 Dependencies

Bank of America maintains an "Underperform" rating, warning that 2026 revenue and margin estimates appear optimistic amid rising investments.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Evercore ISI started coverage with an "In Line" rating, indicating limited short-term potential. These views reflect broader caution around compounded GLP-1 sustainability.

Implications for GLP-1 Access and Weight Management

The market views compounded GLP-1s as a high-risk segment. One scenario preserves regulatory allowances for continued expansion; the other enforces stricter patent rules, curbing supply.

The Strive lawsuit underscores big pharma's resolve to protect the multi-billion-dollar weight-loss market. For patients seeking GLP-1 medications, this could reshape availability through telehealth platforms.

Upcoming quarterly reports will clarify Hims & Hers' navigation of these GLP-1 legal challenges, potentially influencing future access to peptide-based weight therapies.

Source Information

Originally published by Ad Hoc News.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read

Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read

Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Compounded GLP-1

All Compounded GLP-1 articles →

Health & Wellness

The Billion-Dollar Problem Limiting Access to Ozempic, Wegovy, and Zepbound

Despite clinical evidence highlighting the significant health benefits and cost-effectiveness of GLP-1 medications such as Ozempic, Wegovy, and Zepbound, many insurance plans continue to impose restrictions on patient access. This article delves into the financial and practical barriers, as well as the profound consequences for individuals seeking these transformative treatments.

7 min read

Medication Safety

Compounded Ozempic and Zepbound Still Widely Available After Shortages End

Despite the FDA declaring an end to drug shortages for popular weight loss medications, a new study finds compounded versions remain easily accessible. Understanding the safety implications and regulatory landscape is crucial for patient health.

8 min read

Health & Wellness

Semaglutide Telehealth: From The Access Boom To Regulatory Reckoning

The rapid rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity and diabetes care, generating billions in revenue for major manufacturers while creating unprecedented demand for weight management solutions. Telehealth platforms initially emerged as a critical access channel, offering convenient prescriptions and more affordable compounded versions during national shortages. Yet by 2025 and 2026, the sector faced a sharp pivot as FDA actions resolved shortages and curtailed large-scale compounding operations.

7 min read

More in GLP-1 Medications

GLP-1 Medications

South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs

One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.

4 min read

GLP-1 Medications

Cardiologist: GLP-1 Drugs Benefits Beyond Weight Loss for Heart, Liver

Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.

1 min read

GLP-1 Medications

Seoul Hoards 66% of GLP-1 Supply as High-Risk Areas Lack

Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.

2 min read